Skip to main content

Advertisement

Table 2 Cytotoxicity of compounds 9, 10, 11a, 11b, 12, 13, and 14 against hepatocellular carcinoma cell line HePG2

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL Viability (%)/compound
9 10 11a 11b 12 13 14
500 8.43 8.32 23.84 10.32 4.29 4.83 3.74
250 15.82 16.01 48.67 19.47 11.82 12.56 8.91
125 24.67 23.65 72.89 27.93 20.49 19.74 14.82
62.5 30.93 29.86 90.31 38.76 26.54 28.63 20.94
31.25 41.28 37.40 98.16 50.37 32.75 35.16 25.86
15.6 48.71 46.89 100 68.24 41.87 46.29 31.43
7.8 62.39 58.62 100 81.49 55.46 57.18 37.82
3.9 78.24 73.94 100 90.65 73.82 70.42 45.27
2 88.65 81.47 100 97.34 81.46 83.29 50.94
1 94.27 89.53 100 100 88.73 89.64 62.35
0 100 100 100 100 100 100 100